All In Biotech

Drug Trial Radar · NCT00578929

Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients

Last checked: Nov 19, 2026Latest source record: Mar 2, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,388 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,388

Actual

Start

Sep 2007

Primary completion

Nov 2008

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Dec 21, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6 to 11 years with a history of seasonal allergic rhinitis.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • Olopatadine Hydrochloride Nasal Spray 0.6%Drug

    Olopatadine HCl 1 or 2 sprays per nostril twice daily

  • VehicleDrug

    Vehicle 1 or 2 sprays per nostril twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)Time frame: Baseline through 2 weeks after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kenilworth/IL

    Kenilworth, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.